Literature DB >> 11467767

Different levels of TGFbeta, IL-10, IFNgamma and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells.

C A La Porta1, R Comolli.   

Abstract

Bryostatin 1 and phorbol esters reduce the intracellular melanin level in high metastatic overexpressing nPKCdelta BL6 (BL6T) cells, thereby inducing white experimental metastasis in syngeneic mice. We evaluate here the possible differences between white and black metastases induced by both treatments on the proliferative and metastatic potential as well as on the expression of some cytokines involved in the metastatic process such as TGFbeta, IL-10 and IFNgamma. The level of expression of gelatinase A is also considered. White and black metastases induced after the injection of bryostatin 1- or phorbol ester-treated cells into the tail vein of syngenic mice were isolated and analysed for the levels of LDH usually used as markers of cytotoxicity, for the levels of cytokines and gelatinase A or dissociated and cultured in vitro for a few passages. The cultured cells were analysed in vitro for the proliferative capacity and the melanin synthesis. The same cells were also re-injected into syngeneic mice and the number of experimental metastases were counted after 17 days or injected with matrigel in order to quantify the proliferative capacity in vivo. The results show only one significant difference between bryostatin I and phorbol ester, namely the cells obtained from white bryostatin 1-treated cells return to a black phenotype after a few passages in culture. This suggests that PKC mediates many of the biological effects of bryostatin 1 but that its effect is lost in vitro. On the other hand, white and black metastases (at least for metastases induced by BL6T cells treated with phorbol ester) do appear significantly different. In vivo white metastases show lower levels of LDH, lower levels of proliferative capacity into matrigel, higher levels of TGFbeta and IFNgamma and, when re-injected into syngeneic mice, give big black metastases. Therefore, in murine melanoma cells, the treatment with bryostatin I induces the appearance of a white population expressing different levels of TGFbeta, IFNgamma, IL-10 and gelatinase A. Such a white population is more difficult to diagnose and is capable of turning into a more aggressive phenotype under suitable environmental conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11467767     DOI: 10.1023/a:1010913907830

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  28 in total

1.  Activation of protein kinase C-alpha isoform in murine melanoma cells with high metastatic potential.

Authors:  C A La Porta; R Comolli
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

2.  Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

Authors:  R L Hornung; J W Pearson; M Beckwith; D L Longo
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

3.  Overexpression of novel protein kinase C delta in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo.

Authors:  C A La Porta; A Di Dio; D Porro; R Comolli
Journal:  Melanoma Res       Date:  2000-04       Impact factor: 3.599

4.  Angiogenic capacity and lung-colonizing potential in vivo is increased in weakly metastatic B16F1 cells and decreased in highly metastatic BL6 cells by phorbol esters.

Authors:  C A La Porta; R Comolli
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

5.  Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro.

Authors:  T Fujimoto; M A O'Donnell; A Szilvasi; H Yang; R B Duda
Journal:  Cancer Immunol Immunother       Date:  1996-06       Impact factor: 6.968

6.  Transforming growth factor-beta1 inhibits basal melanogenesis in B16/F10 mouse melanoma cells by increasing the rate of degradation of tyrosinase and tyrosinase-related protein-1.

Authors:  M Martínez-Esparza; C Jiménez-Cervantes; F Beermann; P Aparicio; J A Lozano; J C García-Borrón
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

7.  Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.

Authors:  P A Philip; D Rea; P Thavasu; J Carmichael; N S Stuart; H Rockett; D C Talbot; T Ganesan; G R Pettit; F Balkwill
Journal:  J Natl Cancer Inst       Date:  1993-11-17       Impact factor: 13.506

8.  Successful treatment of murine melanoma with bryostatin 1.

Authors:  L M Schuchter; A H Esa; S May; M K Laulis; G R Pettit; A D Hess
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

9.  Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha.

Authors:  J U Dennis; N M Dean; C F Bennett; J W Griffith; C M Lang; D R Welch
Journal:  Cancer Lett       Date:  1998-06-05       Impact factor: 8.679

10.  Interleukin 10 production by human melanoma.

Authors:  T Sato; P McCue; K Masuoka; S Salwen; E C Lattime; M J Mastrangelo; D Berd
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.